Xilio Therapeutics, Inc.
corporate_fare Company Profile
Xilio Therapeutics, Inc. (NASDAQ:XLO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for XLO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for XLO spans 10-Q, 8-K, S-3/A, S-3.
Recent high-impact activity:
- Xilio Q3 10-Q: $122.2M Cash to Q1 2028, But Operating Loss Widens to $11.7M
- Xilio Q2 Revenue Jumps 131% to $18.7M, FDA Clears XTX501 IND
- Xilio Therapeutics Q2 2026: $136M in Cash, Narrower Loss, and FDA Green Light for XTX501
- Xilio Therapeutics Reports Q2 2026 Results, FDA Clears IND for XTX501, and Extends Cash Runway into Q1 2028
- Xilio Therapeutics Reports Q2 Results, Cash Runway Into Q1 2028, NSCLC Data in H2 2027
Financial Snapshot
Short Interest & Short Volume
20.30 days to coverFINRA reported short interest of 382,761 shares in XLO as of the October 30, 2026 settlement, a 4.4% decrease from the prior period — about 20.3 days to cover at its recent average daily volume. On November 20, 2026, 33.9% of XLO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for XLO, detected from its recent SEC filings · based on capital-structure filings through 2026-05-27.
Amended Universal Shelf Registration · Updated At-The-Market (ATM) Program
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →